HartungT. & RovidaC. (2009). Chemical regulators have overreached. Nature, London460, 1080–1081.
2.
BremerS., PellizerC., HoffmannS., SeidleT. & HartungT. (2007). The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. Current Pharmaceutical Design13, 3047–3058.
3.
YoungD., MartinT., VenkatapathyR. & HartenP. (2008). Are the chemical structures in your QSAR correct?QSAR & Combinatorial Science11–12, 1337–1345.
4.
EbbelsT., KeunH., BeckonertO., AnittiH., BollardM., HolmesE., LindonJ. & NicholsonJ. (2003). Toxicity classification from metabonomic data using a density superposition approach: ‘CLOUDS’. Analytica Chimica Acta490, 109–122.
5.
AndersenM.E. & KrewskiD. (2010). The vision of Toxicity Testing in the 21st Century: Moving from discussion to action. Toxicological Sciences117, 17–24.
6.
BatchelorE., LoewerA. & LahavG. (2009). The ups and downs of p53: Understanding protein dynamics in single cells. Nature Reviews Cancer9, 371–377.
7.
SmithD.A. & ObachR.S. (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance and duration of treatment. Chemical Research in Toxicology22, 267–279.
8.
StevensJ.L. & BakerT.K. (2009). The future of drug safety testing: Expanding the view and narrowing the focus. Drug Discovery Today14, 162–167.
9.
KusamaM., ToshimotoK., MaedaK., HiraiY., ImaiS., ChibaK., AkjyamaY. & SugiyamaY. (2010). In silico classification of major clearance pathways of drugs with their physicochemical parameters. Drug Metabolism & Disposition38, 1362–1370.
10.
SEARCH Collaborative Group, LinkE., ParishS., ArmitageJ., BowmanL., HeathS., MatsudaF., GutI., LathropM. & CollinsR. (2002). SLCO1B1 variants and statin-induced myopathy — a genomewide study. New England Journal of Medicine359, 789–799.
